ENOVA is a science and technology “Network on Vaccine Adjuvants”, funded by COST through the EU Framework Programme Horizon 2020. ENOVA is coordinated by the Vaccine Formulation Institute (UK) and brings together European experts and stakeholders working in different areas of adjuvant and vaccine R&D, including both prophylactic and therapeutic applications as well as human and veterinary vaccines. ENOVA’s members include industry, academic, and government institutions. The ultimate goals of the network are to facilitate communication and the exchange of information among its membership, to ensure that new discoveries are widely disseminated so that their potential can be of optimal benefit, to promote the best use of existing adjuvant technologies, and to encourage and support the development of novel adjuvants.
Oct. 13, 2021 10:04 AM
ENOVA STRATEGY ON VIRTUAL NETWORKING
Brankica Filipic has been awarded with VN Grant and to represent ENOVAs plans for virtual activities.
Adjuvants - the unsung heroes of vaccines
Sep. 17, 2021 9:39 AM
Article by ENOVA member Anita Milicic about the history of adjuvants
Virtual Networking Grants
May 21, 2021 10:58 AM
COST has launched Virtual Networking Support and there are two options available:
LIVE Master in Vaccinology
Dec. 2, 2020 11:22 AM
Leading Interational Vaccinology Education
A Programme of Excellence in Learning and Research, Looking for Biochemists, Bioengineers, Biologists, Clinicians, Pharmacists and Veterinarians